{"id":7962,"date":"2025-01-22T17:28:34","date_gmt":"2025-01-22T09:28:34","guid":{"rendered":"https:\/\/regask.com\/?p=7962"},"modified":"2025-01-22T17:28:34","modified_gmt":"2025-01-22T09:28:34","slug":"guide-de-la-fda-sur-la-reglementation-des-medicaments-sur-ordonnance","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/us-fda-ai-drug-regulation-guidance\/","title":{"rendered":"La FDA am\u00e9ricaine annonce un projet de lignes directrices sur l\u2019utilisation de l\u2019IA dans les processus r\u00e9glementaires"},"content":{"rendered":"<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"e019e190-82b2-4137-a598-8f941c192144\" data-message-model-slug=\"gpt-4o\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p>On January 6, 2025, the U.S. Food and Drug Administration (FDA) announced the release of a draft guidance titled \u201cConsiderations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.\u201d This draft guidance marks an important step toward integrating artificial intelligence (AI) into the regulatory decision-making process for drugs and biological products, emphasizing safety, effectiveness, and quality assessments. Through this initiative, the FDA aims to establish a <a href=\"https:\/\/regask.com\/uk-cbd-public-list\/\">risk-based framework<\/a> to evaluate the credibility and reliability of AI models in regulatory contexts.<\/p>\n<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"30ff894f-05e5-4853-9fe5-f143f87341e6\" data-message-model-slug=\"gpt-4o\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p>The FDA\u2019s guidance highlights several critical components:<\/p>\n<h4><strong>1. A Risk-Based Credibility Framework<\/strong><\/h4>\n<p>AI models must be assessed based on their intended use, or <strong>context of use (COU),<\/strong> with varying levels of oversight and stringency depending on the potential impact on patient safety or study reliability.<\/p>\n<p>Key factors include:<\/p>\n<ul>\n<li>Performance criteria<\/li>\n<li>Risk mitigation strategies<\/li>\n<li>Tailored documentation requirements<\/li>\n<\/ul>\n<h4><strong>2. Scope of AI Applications<\/strong><\/h4>\n<p>The guidance focuses on AI&#8217;s role in <strong>nonclinical, clinical, post marketing, and manufacturing<\/strong> phases, specifically for regulatory decisions related to drug safety, effectiveness, and quality.<br \/>\nExcluded from the guidance are:<\/p>\n<ul>\n<li>AI in drug discovery<\/li>\n<li>Applications enhancing operational efficiency without direct patient or study impacts<\/li>\n<\/ul>\n<h4><strong>3. Early Engagement with FDA<\/strong><\/h4>\n<p>The FDA strongly encourages sponsors to engage early, especially for higher-risk applications like <strong>post marketing pharmacovigilance.<\/strong> Clear documentation and alignment with the agency&#8217;s expectations are key to a smooth evaluation process.<\/p>\n<h4><strong>4. Encouraging Innovation in Pharmacovigilance<\/strong><\/h4>\n<p>To foster innovation, the FDA has also launched the <strong>Emerging Drug Safety Technology Meeting (EDSTM) Program,<\/strong> a platform for discussing new technologies and their potential applications in pharmacovigilance.<\/p>\n<p>The FDA is calling on industry leaders, researchers, and other stakeholders to provide feedback on the draft guidance by <strong>April 7, 2025.<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\">\n<div class=\"items-center justify-start rounded-xl p-1 flex\">\n<div class=\"flex items-center justify-center rounded-lg text-token-text-secondary\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Le 6 janvier 2025, la Food and Drug Administration (FDA) des \u00c9tats-Unis a annonc\u00e9 la publication d&#039;un projet de lignes directrices intitul\u00e9 \u00ab\u00a0Consid\u00e9rations relatives \u00e0 l&#039;utilisation de l&#039;intelligence artificielle pour soutenir la prise de d\u00e9cision r\u00e9glementaire concernant les m\u00e9dicaments et les produits biologiques\u00a0\u00bb. Ce projet de lignes directrices marque une \u00e9tape importante vers l&#039;int\u00e9gration de l&#039;intelligence artificielle (IA) dans le processus d\u00e9cisionnel r\u00e9glementaire des m\u00e9dicaments et\u2026<\/p>","protected":false},"author":43,"featured_media":7973,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[527,35],"tags":[609,459,461,496,498],"class_list":["post-7962","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-united-states-regulations","category-pharma-biotech-latest-insights","tag-guideline","tag-innovation-health","tag-ai-driven","tag-market-authorization-regs","tag-drug-development-regs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>US FDA Draft Guidance on AI in Drug Regulation | RegASK<\/title>\n<meta name=\"description\" content=\"US FDA releases draft guidance on AI use in drug regulation. Feedback due by April 7, 2025. Read more at RegASK.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/guide-de-la-fda-sur-la-reglementation-des-medicaments-sur-ordonnance\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"US FDA Announces Draft Guidance on AI Use in Regulatory Decision-Making for Drug and Biological Products\" \/>\n<meta property=\"og:description\" content=\"US FDA releases draft guidance on AI use in drug regulation. Feedback due by April 7, 2025. Read more at RegASK.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/guide-de-la-fda-sur-la-reglementation-des-medicaments-sur-ordonnance\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-22T09:28:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2025\/01\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"US FDA Announces Draft Guidance on AI Use in Regulatory&hellip;\",\"datePublished\":\"2025-01-22T09:28:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/\"},\"wordCount\":294,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png\",\"keywords\":[\"Guideline\",\"Innovation Health\",\"AI-Driven\",\"Market authorization regs\",\"Drug Development Regs\"],\"articleSection\":[\"United States\",\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/\",\"name\":\"US FDA Draft Guidance on AI in Drug Regulation | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png\",\"datePublished\":\"2025-01-22T09:28:34+00:00\",\"description\":\"US FDA releases draft guidance on AI use in drug regulation. Feedback due by April 7, 2025. Read more at RegASK.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/us-fda-ai-drug-regulation-guidance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png\",\"width\":800,\"height\":600,\"caption\":\"Us Fda Announces Draft Guidance Ai Use Regulatory Decision Making Drug Biological Products\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Projet de lignes directrices de la FDA am\u00e9ricaine sur l&#039;IA dans la r\u00e9glementation des m\u00e9dicaments | RegASK","description":"La FDA am\u00e9ricaine publie un projet de lignes directrices sur l&#039;utilisation de l&#039;IA dans la r\u00e9glementation des m\u00e9dicaments. Les commentaires doivent \u00eatre soumis avant le 7 avril 2025. Pour en savoir plus, rendez-vous sur RegASK.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/guide-de-la-fda-sur-la-reglementation-des-medicaments-sur-ordonnance\/","og_locale":"fr_FR","og_type":"article","og_title":"US FDA Announces Draft Guidance on AI Use in Regulatory Decision-Making for Drug and Biological Products","og_description":"US FDA releases draft guidance on AI use in drug regulation. Feedback due by April 7, 2025. Read more at RegASK.","og_url":"https:\/\/regask.com\/fr\/guide-de-la-fda-sur-la-reglementation-des-medicaments-sur-ordonnance\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2025-01-22T09:28:34+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/01\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/#article","isPartOf":{"@id":"https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"US FDA Announces Draft Guidance on AI Use in Regulatory&hellip;","datePublished":"2025-01-22T09:28:34+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/"},"wordCount":294,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/01\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png","keywords":["Guideline","Innovation Health","AI-Driven","Market authorization regs","Drug Development Regs"],"articleSection":["United States","Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/","url":"https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/","name":"Projet de lignes directrices de la FDA am\u00e9ricaine sur l&#039;IA dans la r\u00e9glementation des m\u00e9dicaments | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/01\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png","datePublished":"2025-01-22T09:28:34+00:00","description":"La FDA am\u00e9ricaine publie un projet de lignes directrices sur l&#039;utilisation de l&#039;IA dans la r\u00e9glementation des m\u00e9dicaments. Les commentaires doivent \u00eatre soumis avant le 7 avril 2025. Pour en savoir plus, rendez-vous sur RegASK.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/us-fda-ai-drug-regulation-guidance\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/01\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/01\/us-fda-announces-draft-guidance-ai-use-regulatory-decision-making-drug-biological-products.png","width":800,"height":600,"caption":"Us Fda Announces Draft Guidance Ai Use Regulatory Decision Making Drug Biological Products"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Le syst\u00e8me d&#039;exploitation d&#039;IA r\u00e9glementaire pour les \u00e9quipes performantes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/7962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=7962"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/7962\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/7973"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=7962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=7962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=7962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}